Avantel Q1FY27 net profit rises 65% YoY to ₹761.77 lakh
Avantel Limited reported a standalone net profit of ₹761.77 lakh for the first quarter ended June 30, 2026, a significant increase from ₹46 lakh in the same quarter of the previous year. Revenue from operations grew to ₹7012.34 lakh from ₹518 lakh YoY, while EBITDA margin expanded to 27.30%. The Board approved the unaudited financial results and made several key appointments, including the re-appointment of Mr. Abburi Siddhartha Sagar and the appointment of Mr. Peddi Bala Bhaskar Rao.

*this image is generated using AI for illustrative purposes only.
Avantel Limited reported a standalone net profit of ₹761.77 lakh for the first quarter ended June 30, 2026, reflecting a strong year-on-year (YoY) growth compared to ₹46 lakh in the same quarter of the previous year. Revenue from operations for the quarter stood at ₹7012.34 lakh, up from ₹518 lakh in the corresponding quarter of the prior year. The company's total income for Q1FY27 was ₹7023.89 lakh, while revenue from operations in the preceding quarter ended March 31, 2026, was ₹6314.66 lakh.
The Board of Directors, at its meeting held on July 11, 2026, approved the unaudited standalone and consolidated financial results for the period. The results were reviewed by the Statutory Auditors and the Audit Committee. The company operates in a single segment, focusing on communications and signal processing products, and noted that its principal customer is an organization controlled by the Government of India, which influenced its decision regarding loss allowance provisions.
Financial Performance
Avantel's standalone financial results for the quarter ended June 30, 2026, reflect broad-based improvement across key metrics on both a sequential and year-on-year basis. EBITDA for the quarter came in at ₹191 lakh, compared to ₹114 lakh in Q1 of the previous year, while the EBITDA margin expanded to 27.30% from 21.89% YoY. Total expenses for the quarter were ₹5931.69 lakh, and profit before tax stood at ₹1092.20 lakh. The basic and diluted earnings per equity share (face value ₹2) stood at ₹0.29 for the quarter.
The following table summarises the standalone financial performance across reporting periods (all figures in ₹ lakh unless stated):
| Particulars: | Q1FY27 (30/06/2026) Unaudited | Q4FY26 (31/03/2026) Audited | FY26 (31/03/2026) Audited |
|---|---|---|---|
| Revenue from Operations: | ₹7012.34 | ₹6314.66 | ₹22135.23 |
| Total Income: | ₹7023.89 | ₹6423.54 | ₹22380.90 |
| Total Expenses: | ₹5931.69 | ₹5461.29 | ₹19163.69 |
| Net Profit for the Period: | ₹761.77 | ₹705.23 | ₹2249.97 |
| Earnings per Share (Basic): | ₹0.29 | ₹0.29 | ₹0.92 |
The YoY performance highlights a significant improvement across key operating metrics:
| Metric: | Q1FY27 | Q1FY26 | Change (YoY) |
|---|---|---|---|
| Net Profit: | ₹761.77 lakh | ₹46 lakh | Higher YoY |
| Revenue from Operations: | ₹7012.34 lakh | ₹518 lakh | Higher YoY |
| EBITDA: | ₹191 lakh | ₹114 lakh | Higher YoY |
| EBITDA Margin: | 27.30% | 21.89% | Expanded YoY |
On a consolidated basis, which includes subsidiary iMeds Global Private Limited, the company reported a net profit of ₹539.46 lakh for Q1FY27, compared to ₹477.47 lakh in the previous quarter. Total consolidated revenue from operations was ₹7042.16 lakh. The subsidiary reported a net loss of ₹222.31 lakh for the quarter, which the management stated is not material to the Group.
Board Decisions and Appointments
The Board approved the revision of remuneration for Mr. Abburi Siddhartha Sagar, Executive Director (Strategy & Business Development), from ₹48.00 Lakhs per annum to ₹55 Lakhs per annum, effective July 11, 2026. Additionally, the Board approved the re-appointment of Mr. Abburi Siddhartha Sagar for a further term of five years commencing March 8, 2027, subject to shareholder approval via postal ballot.
Mr. Peddi Bala Bhaskar Rao was appointed as an Additional Director designated as Director (Operations) for a term of three years effective July 11, 2026, subject to shareholder approval. The Board also approved the re-appointment of Mr. Vyasabhattu Ramchander as an Independent Director for a second consecutive term of five years from May 6, 2027, subject to approval by a special resolution through postal ballot. The Board further reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders' Relationship Committee with immediate effect.
Historical Stock Returns for Avantel
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.32% | -1.57% | -9.62% | +4.16% | +22.96% | -16.65% |
What factors drove the massive revenue surge from ₹518 lakh to ₹7012 lakh YoY?
How will the company address the ₹222.31 lakh net loss reported by its subsidiary, iMeds Global Private Limited?
What is the outlook for maintaining the expanded EBITDA margin of 27.30% over the coming quarters?


































